Inventi Impact - Biosimilars & Biopharmaceuticals
Formerly Inventi Rapid/Impact: Biosimilars


  • Inventi:pbs/77/14
    Hitesh Chopra, Sandeep Kumar, Punam Gaba

    Biosimilars are defined as the biotechnological products having patent expired and are found to possess almost similar properties as that of innovator products. In the next coming years there is great line up standing for patent expiry means there would be great blockbuster coming now. India is a hub of generic medicines means similar trend will be followed for the production of biosimilar products. So there is great need for the development of some strict guidelines as the principles followed in case of pharmaceutical drugs could not be applied over it. In this review the present scenario regarding the biosimilar is provided and also describes the drawbacks of the present system.

    How to Cite this Article
    Cite this article as: Hitesh Chopra, Sandeep Kumar, Punam Gaba. Biosimilars or Biogenerics: Its Present Scenario. Inventi Impact: Biosimilars, 2014(4):151-153, 2014.
    Download Full Text